Oxular’s technologies were developed together to find solutions that would solve significant remaining unmet challenges in retinal care. Together, these systems will transform the treatment of retinal disorders.
Oxular’s Chief Scientific Officer, Ron Yamamoto, shared an overview of Oxular’s drug delivery formulations at the OIS Drug Delivery meeting.
Our CEO, Tom Cavanagh, presented an overview of Oxular’s retinal therapeutics platform at Eyecelerator, during AAO 2021. It was a
Oxular was mentioned in this great article by Dr. Sivaprasad in Retina Today, on the promise of reduced treatment burden
Dr. Asmus brings two decades of experience leading global clinical and translational research programs for both retinal and rare diseases.
Led by specialist life sciences investor, Forbion Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for
Appointment builds Oxular’s team as it prepares to enter human clinical studies evaluating OXU-001 OXFORD, UK, 8 February 2021 –
General
+44 (0)1865 636200
inquiries@oxular.com
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Limited company registered in
England and Wales
Registration No. 09331313
VAT No. GB 244 5883 81
Copyright Oxular Limited
Media
+1 617 895 9511
monique@thrustsc.com
Monique Allaire
Thrust
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting